Clinical Trials Logo

ISS Stage II Plasma Cell Myeloma clinical trials

View clinical trials related to ISS Stage II Plasma Cell Myeloma.

Filter by:
  • None
  • Page 1

NCT ID: NCT03267888 Completed - Clinical trials for Recurrent Plasma Cell Myeloma

Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma

Start date: May 29, 2018
Phase: Phase 1
Study type: Interventional

This pilot clinical trial studies the side effects of pembrolizumab and radiation therapy in treating patients with stage I-III multiple myeloma that has come back after a period of improvement or that does not respond to treatment. Monoclonal antibodies, such as pembrolizumab, may block cancer growth in different ways by targeting certain cells. Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. Giving pembrolizumab and radiation therapy may work better in treating patients with stage I-III multiple myeloma.

NCT ID: NCT02727803 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia

Personalized NK Cell Therapy in CBT

Start date: May 19, 2016
Phase: Phase 2
Study type: Interventional

This phase II clinical trial studies how well personalized natural killer (NK) cell therapy works after chemotherapy and umbilical cord blood transplant in treating patients with myelodysplastic syndrome, leukemia, lymphoma or multiple myeloma. This clinical trial will test cord blood (CB) selection for human leukocyte antigen (HLA)-C1/x recipients based on HLA-killer-cell immunoglobulin-like receptor (KIR) typing, and adoptive therapy with CB-derived NK cells for HLA-C2/C2 patients. Natural killer cells may kill tumor cells that remain in the body after chemotherapy treatment and lessen the risk of graft versus host disease after cord blood transplant.

NCT ID: NCT01619761 Active, not recruiting - Clinical trials for Myelodysplastic Syndrome

NK Cells in Cord Blood Transplantation

Start date: May 3, 2013
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best way to give natural killer cells and donor umbilical cord blood transplant in treating patients with hematological malignancies. Giving chemotherapy with or without total body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells and natural killer cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.